Biotech Investing argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
Biotech Investing argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia
Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth
Apex Commences Drilling at Jersey Emerald Property and Announces Amendment to Terms of Lithium Creek Option Agreement
